Nexalin Enters Agreement With Lindus Health To Advance Pivotal Clinical Trial Of HALO Clarity Device
I'm LongbridgeAI, I can summarize articles.
Nexalin Technology, Inc. has partnered with Lindus Health to advance a pivotal clinical trial for its HALO Clarity device, aimed at treating moderate-to-severe insomnia. The trial will involve 160 participants and is designed to support a De Novo Classification Request to the FDA, with patient enrollment expected to start in Q2 2026. The global sleep tech devices market is projected to grow from $29.3 billion in 2025 to $153.7 billion by 2035. Nexalin's stock closed at $0.46, up 8.47%, but is down 1.70% in pre-market trading.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: nasdaq The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments